Dr. Arun Menawat reports

PROFOUND MEDICAL APPOINTS TOM TAMBERRINO AS CHIEF COMMERCIAL OFFICER

Profound Medical Corp. today appointed Tom Tamberrino as its new chief commercial officer. Abbey Goodman, the company's current chief commercial officer, will transition to leading Profound's strategic partnerships, continuing to report to the company's chief executive officer and chairman, Arun Menawat, PhD.

Mr. Tamberrino has an accomplished history of sales and marketing leadership, business development, executive management and entrepreneurial success, most of which was gained in the United States health care industry.

Mr. Tamberrino served as vice-president, sales and marketing, at Novadaq Technologies Inc. immediately prior to pursuing his most recent entrepreneurial endeavours outside of the medical technology space. Dr. Menawat, who was chairman, president and chief executive officer of Novadaq during Mr. Tamberrino's tenure at that company, directly recruited Mr. Tamberrino to serve as Profound's new CCO.

While at Novadaq, Mr. Tamberrino helped to establish the company as the market leader in near infrared fluorescence imaging for visualization of blood flow and tissue perfusion, before, during and after surgical procedures. He built a direct United States sales and marketing organization driving an annual revenue run rate of approximately $27-million at the end of 2012, to more than $82-million in annualized revenues when, in 2017, Novadaq was acquired by Stryker Corp. for approximately $701-million. Mr. Tamberrino remained until 2018 to assist with the integration of the Novadaq business into the Stryker organization. Earlier in his career, he held progressive sales management positions with LifeCell Corp., most recently serving as area director, where he managed a 50-person sales team across the northeast of the United States and Canada that marketed LifeCell's regenerative tissue matrices alongside Novadaq's intraoperative perfusion assessment technology for complex trauma, cancer and general surgery cases to colorectal, general, plastic, transplant and trauma surgeons. Mr. Tamberrino received a bachelor of science degree in marketing, minor in psychology, from Georgetown University, and a master of business administration from Emory University.

"This is actually the second time that I have personally recruited Tom to build and manage the sales organizations of companies led by me as CEO -- first from LifeCell to Novadaq and now to Profound," said Dr. Menawat. "The permanent CPT Category 1 codes for Tulsa going into effect at the beginning of 2025 represent an anticipated major inflection point for our business. Now is the perfect time to bring in a sales and marketing executive that I have worked with closely in the past; and one who has earned my trust, respect and most importantly, confidence, in the process. I am honoured and excited to welcome Tom to Profound."

"As naturally inclined as I was to be warmly receptive to Arun's overtures to join him at Profound, I wanted to be certain that I would be able to hit the ground running," commented Mr. Tamberrino. "And, like many men that I had spoken to, I naturally wondered why any prostate disease patient who was presented with an informed choice of available treatment options would not choose Tulsa given its ability to effectively, safely and efficiently treat an unrivalled variety of prostate cancer and/or benign prostatic hyperplasia (BPH) patients. So, I did a lot of diligence. As a result, I am convinced that widespread adoption of Tulsa will be driven mostly by increasing patient and physician awareness, and by ensuring Tulsa can be readily accessed in the most suitable settings, including hospitals, ASCs and private practice offices/facilities. Importantly, with reimbursement now on the horizon, I was not able to identify any remaining major obstacles to widespread adoption of Tulsa-Pro. I am looking forward to working with Arun, Abbey and the rest of the Profound team to maximize the tremendous opportunity we see ahead."

Commenting on Ms. Goodman's transition to leading Profound's strategic partnerships, Dr. Menawat said: "Over the past several months, Abbey has helped lead the charge as we have begun building closer relationships with MR and other medical technology companies to help create a total diagnostic and interventional MRI solution to support the modern treatment pathway that allows for more accurate and precise prostate disease diagnosis, treatment with the Tulsa Procedure, and post-treatment follow-up. I am excited that Abbey has accepted this newly created and important role, and look forward to her continuing contributions to realizing this shared MR-centric vision."

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing Tulsa-Pro, a technology that combines real-time MRI (magnetic resonance imaging), robotically driven transurethral ultrasound and closed-loop temperature feedback control. Tulsa-Pro is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. Tulsa-Pro has the potential to be a flexible technology in customizable prostate ablation, including intermediate-stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large-volume benign prostatic hyperplasia (BPH). Tulsa-Pro is CE (Conformite Europeenne) marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).

Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a humanitarian device exemption for the treatment of osteoid osteoma. The company is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

We seek Safe Harbor.